Recent updates concern
Alexandria Real Estate Equities (ARE). Despite reporting a 10.2% growth, the company has slashed its dividend and struggled with impairment charges in Long Island City (LIC). Simultaneously, the business completes a
32-year milestone in life science real estate, with substantial impact on human health advancement. Nevertheless, the
50% share price fall has stirred questions about its 2025 prospect.
Robeco Institutional Asset Management divested 20,936 ARE shares.
Morgan Stanley started ARE coverage, recommending an Equal-Weight stance.
Rosen law firm spurred ARE investors to safeguard their investments as securities lawsuits arise. ARE overperformed competitor stocks amid volatility, following valuation reviews and a sharp price tumble. The company also endured a hefty dividend cut, weaker Q3 2025 performance, and lawsuit-induced impairment, adjusting its narrative due to LIC issues and class actions. It then liquidated a LIC life sciences hub for $35M. Further, ARE revised its stock repurchase program, refreshing it to $500M, and initiated strategic partnerships with
Lilly to further drug development via the One Alexandria Square Megacampus in San Diego's Torrey Pines. Meanwhile, ARE saw a downgraded outlook from S&P and a significant drop in 2025, sparking reconsideration by investors.
Alexandria Real Estate Equities ARE News Analytics from Fri, 26 Sep 2025 07:00:00 GMT to Sat, 10 Jan 2026 18:02:54 GMT -
Rating -6
- Innovation 2
- Information 8
- Rumor -4
